HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Found Negligent In Suit Linking Talc To Cancer

This article was originally published in The Tan Sheet

Executive Summary

While no monetary damages were awarded, a federal court jury in South Dakota found Johnson & Johnson negligent for failing to warn that talc in its body powders may be linked to cancer. However, the jury did not find that J&J’s products were defective without such a warning.

You may also be interested in...



FDA: No Asbestos Found In Talc Products Sampled, But Results Limited

Following reports of asbestos in talc and talc-containing products overseas, FDA conducted a survey of suppliers and products on the U.S. market, finding no detectable levels of asbestos.

CTFA Urges NTP To Reconsider Talc Data For Carcinogenicity Review

The Cosmetic, Toiletry and Fragrance Association encouraged the National Toxicology Program to reconsider data submitted to the agency by the association in 2002 on the safety of cosmetic talc as part of the agency's review of the ingredient for possible listing in the 12th Report on Carcinogens

Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024

Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel